Loading...
Effective topical preexposure prophylaxis could fill an important gap in HIV prevention options for women. However, this goal has proven elusive. One of the main barriers has been difficulty in sustaining high levels of adherence in clinical trials. Drug-eluting vaginal rings might improve adherence because they depend less on user compliance than oral or gel preparations.
Researchers recently assessed whether a reservoir intravaginal ring (IVR) device could deliver tenofovir continuously over 28 days and protect macaques from acquiring simian human immunodeficiency virus (SHIV). High mean vaginal fluid concentrations of tenofovir disoproxil fumarate (TDF; 72,000 ng/mL) and its hydrolysis product tenofovir (100 ng/mL) were achieved. Tenofovi…